Moderna Inc
As on 18 Apr, 2026 | 01:29 IST
| Open | 55.68 |
| Previous Close | 54.68 |
| Beta | 0.83 |
| High | 56.00 |
| Low | 52.95 |
| TTM EPS See historical trend | -7.27(+21.66% YoY) |
| 52 Week High | 59.52 |
| 52 Week Low | 22.32 |
| TTM PE See historical trend | -7.39(Low PE) |
| Mkt. Cap ($ Billion) | 20.57 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 53.25 |
| 10 | 51.94 |
| 20 | 51.42 |
| 50 | 50.34 |
| 100 | 42.27 |
| 200 | 34.79 |
Returns
| 1 Week | 5.42% | |
| 1 Month | -0.39% | |
| 3 Months | 28.39% | |
| YTD | 82.16% | |
| 1 Year | 117.36% | |
| 3 Years | -62.69% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Amgen | 355.30 | 1.69 | 190.99 | 16.26 | 21.85 | 2.95 | 391.23/261.50 | -1.62 | Very Bearish |
| Gilead Sciences | 137.64 | -0.66 | 171.62 | 16.89 | 8.15 | 2.57 | 157.27/95.31 | -4.68 | Neutral |
| Vertex Pharmaceuticals | 441.19 | 1.27 | 113.98 | 23.97 | 18.41 | -- | 510.73/362.97 | -4.55 | Very Bearish |
| Regeneron Pharmaceuticals | 750.57 | 0.61 | 82.37 | 16.91 | 44.38 | 0.46 | 821.11/476.79 | -1.12 | Very Bearish |
| Incyte | 97.80 | 2.60 | 21.96 | 14.41 | 6.79 | -- | 112.20/56.16 | 3.84 | Bullish |
Market news
- Wall St ends mixed, notches weekly gains as investors parse Middle East negotiationsApril 11, 2026 8:53 AM
- Wall Street skids as Middle East turmoil fans inflation fearMarch 21, 2026 9:02 AM
- Wall Street closes lower, posts weekly loss as war on Iran fuels inflation worriesMarch 14, 2026 8:59 AM
- US stocks close down as oil spikes 12%, job market weakensMarch 7, 2026 9:27 AM
About the company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.